Becker's Spine Review

Becker's Spine Review Nov/Dec 2016

Issue link: https://beckershealthcare.uberflip.com/i/759246

Contents of this Issue

Navigation

Page 14 of 47

15 DEVICES & INNOVATION The power of revolution. CELLXTRACT is a revolutionary extraction tool that provides high recovery of cells and their associated signals that, when combined with complementary bone graft substitutes, deliver key components of the bone healing environment. The design automatically repositions the aspiration cannula during extraction to draw from a fresh channel, maximizing cell counts while minimizing the dilution from peripheral blood. The Art and Science of Orthobiologics. Learn more about CELLXTRACT and our full portfolio at BioventusSurgical.com CELLXTRACT is intended for single use for aspiration of bone marrow or autologous blood using a standard piston syringe. ©2016 Bioventus LLC. I Bioventus, the Bioventus logo, and CELLXTRACT are registered trademarks of Bioventus LLC. I SMK-001880 I 09/16 Cannula Design Disc Replacement vs. Spinal Fusion: 5 Key Notes on Adjacent Segment Disease By Laura Dyrda A new study published in Spine examines cervical disc arthroplasty and anterior cervical discectomy and fusion for adjacent segment disease. The study authors searched PubMed, EMBASE and Cochrane Central Regis- ter of Controlled Trials to include data from randomized controlled trials for adjacent segment disease after disc replacement and fusion. There were two independent authors selecting qualified studies. There were 14 randomized controlled trials with 3,235 participants who had at least a two-year follow-up included in this meta-analysis. There were 1,696 disc replacement patients and 1,539 fusion patients. The researchers found: 1. The patients who underwent disc replacement reported superior out- comes when compared with spinal fusion patients. 2. The disc replacement patients re- ported a lower rate of adjacent seg- ment disease than the fusion patients. 3. There were significantly fewer re- operations due to adjacent segment disease among the disc replacement patients than the fusion patients. 4. The study authors concluded, "CDA may be a better surgical proce- dure to reduce the incidence of ASD for patients with cervical disc disease compared with ACDF." 5. The study authors mentioned ad- ditional studies should focus on the patients with long-term follow-up to evaluate ASD among the two proce- dures. n Global Market for Cervical Total Disc Replacement Devices to Reach $1.75B by 2021: 5 Notes By Jessica Kim Cohen T he global market for cervical total disc replacement devices will surpass $1 billion by 2021, according to a Persistence Market Research report. Among its findings, the report notes: 1. The global market for total disc re- placement devices reached $409.7 million in 2014, accounting for 66 per- cent of the global total disc replace- ment market. 2. The cervical total disc replacement devices market is expected to reach $1.75 billion by the end of 2021, grow- ing at a compound annual growth rate of 23.1 percent. 3. Key market players include DePuy Synthes, Globus Medical, Medtronic and NuVasive. 4. Trends influencing the market in- clude investment in research and de- velopment, technological advance- ments and recent acquisitions and mergers. 5. The surge in market growth is at- tributed to the prevalence of chronic diseases, the aging population and the low revision rate of cervical disc re- placement surgery. n

Articles in this issue

Links on this page

view archives of Becker's Spine Review - Becker's Spine Review Nov/Dec 2016